Latest & greatest articles for montelukast

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on montelukast or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on montelukast and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for montelukast

1. Montelukast

Montelukast Top results for montelukast - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search (...) button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for montelukast The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory

Trip Latest and Greatest2018

2. Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: A randomized controlled trial

Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: A randomized controlled trial 28894551 2018 11 13 2008-5842 9 7 2017 Jul Electronic physician Electron Physician Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: A randomized controlled trial. 4890-4894 10.19082/4890 Otitis media is one of the most common infections among children and is a complication in about 30% of common colds. The most common (...) complication of acute otitis media is otitis media with effusion. Some studies have reported the effects of montelukast and mometasone nasal spray in treatment of otitis media with effusion. However, current information is inadequate in this issue. To compare the effectiveness of montelukast and mometasone nasal spray in treatment of otitis media with effusion in children attending Koodakan hospital in Bandar Abbas, Iran. This randomized controlled trial was done on 2- to 6-year-old children attending

Electronic physician2017 Full Text: Link to full Text with Trip Pro

3. Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma 26915674 2016 07 04 2016 07 04 1097-6825 138 1 2016 Jul The Journal of allergy and clinical immunology J. Allergy Clin. Immunol. Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma. 142-149.e8 10.1016/j.jaci.2015.11.035 S0091-6749(16)00107-X Roflumilast, a selective phosphodiesterase 4 inhibitor (...) , has been shown to provide modest improvements in lung function in patients with mild-to-moderate asthma, but its efficacy in patients with moderate-to-severe asthma has not been assessed. We hypothesized that this drug might provide benefit if combined with montelukast, a leukotriene receptor antagonist, in patients whose symptoms are uncontrolled by inhaled corticosteroids and long-acting β-agonists. We sought to examine the efficacy, safety, and mode of action of the addition of roflumilast

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

4. Parent-determined oral montelukast therapy for preschool wheeze with stratification for arachidonate 5-lipoxygenase (ALOX5) promoter genotype: a multicentre, randomised, placebo-controlled trial

Parent-determined oral montelukast therapy for preschool wheeze with stratification for arachidonate 5-lipoxygenase (ALOX5) promoter genotype: a multicentre, randomised, placebo-controlled trial Parent-determined oral montelukast therapy for preschool wheeze with stratification for arachidonate-5-lipoxygenase (ALOX5) promoter genotype. Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested (...) could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} The study found no clear benefit of intermittent montelukast in young children with wheeze. Further research is need to determine if a variant allele of ALOX5 identifies individuals who are more responsive to montelukast. {{author}} {{($index , , , , , , , , , , , , & . Chinedu

NIHR HTA programme2015 Full Text: Link to full Text with Trip Pro

5. Montelukast for sleep apnea: a review of the clinical effectiveness, cost effectiveness, and guidelines

Montelukast for sleep apnea: a review of the clinical effectiveness, cost effectiveness, and guidelines Montelukast for sleep apnea: a review of the clinical effectiveness, cost effectiveness, and guidelines Montelukast for sleep apnea: a review of the clinical effectiveness, cost effectiveness, and guidelines CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation CADTH. Montelukast for sleep apnea: a review of the clinical effectiveness, cost effectiveness, and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2014 Authors' conclusions One study found that montelukast improved respiratory disturbances in children with mild to moderate obstructive sleep apnea (OSA). No published trials regarding the use of montelukast in adults with OSA were identified

Health Technology Assessment (HTA) Database.2014

6. Montelukast

Montelukast USE OF MONTELUKAST IN PREGNANCY 0344 892 0909 USE OF MONTELUKAST IN PREGNANCY (Date of issue: August 2015 , Version: 2.1 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Montelukast is a cysteinyl leukotriene type-1 receptor (...) antagonist licensed as an anti-asthmatic medication for patients inadequately controlled by inhaled corticosteroids or short-acting beta-agonists, and for asthmatics with exercise-induced bronchoconstriction. Although the available data are limited both by lack of power and/or formal statistical analysis in some studies, there is currently no good evidence that montelukast exposure during pregnancy increases the overall risk of congenital malformation, spontaneous abortion, intrauterine death, decreased

UK Teratology Information Service2014

7. Randomised controlled trial: Montelukast potentially efficacious in children with non-severe obstructive sleep apnoea in the short term

Randomised controlled trial: Montelukast potentially efficacious in children with non-severe obstructive sleep apnoea in the short term Montelukast potentially efficacious in children with non-severe obstructive sleep apnoea in the short term | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Montelukast potentially efficacious in children with non-severe obstructive sleep apnoea in the short term Article Text Therapeutics Randomised controlled trial Montelukast potentially efficacious in children with non-severe obstructive sleep apnoea in the short

Evidence-Based Medicine (Requires free registration)2013

8. Oral montelukast in acute asthma exacerbations: a randomised, double-blind, placebo-controlled trial

Oral montelukast in acute asthma exacerbations: a randomised, double-blind, placebo-controlled trial 20956393 2010 12 14 2011 03 24 2012 11 15 1468-3296 66 1 2011 Jan Thorax Thorax Oral montelukast in acute asthma exacerbations: a randomised, double-blind, placebo-controlled trial. 7-11 10.1136/thx.2010.135038 Although leukotriene receptor antagonists have an established role in the management of patients with chronic asthma, their efficacy in an acute asthma exacerbation is not fully known. 87 (...) adults with acute asthma requiring hospitalisation were randomly assigned to receive either montelukast 10 mg or placebo on admission and every evening thereafter for 4 weeks (when they were reviewed as outpatients). All patients were admitted under the care of a consultant chest physician and received full care for acute asthma according to the British Thoracic Society guidelines. The primary end point was the difference in peak expiratory flow (PEF) between active and placebo treatment the morning

EvidenceUpdates2011

9. Effect of addition of single dose of oral montelukast to standard treatment in acute moderate to severe asthma in children between 5 and 15 years of age: a randomised, double-blind, placebo controlled trial

Effect of addition of single dose of oral montelukast to standard treatment in acute moderate to severe asthma in children between 5 and 15 years of age: a randomised, double-blind, placebo controlled trial 20522464 2010 06 16 2010 09 08 2012 11 15 1468-2044 95 7 2010 Jul Archives of disease in childhood Arch. Dis. Child. Effect of addition of single dose of oral montelukast to standard treatment in acute moderate to severe asthma in children between 5 and 15 years of age: a randomised, double (...) -blind, placebo controlled trial. 540-3 10.1136/adc.2009.168567 To study the effect of the addition of a single dose of oral montelukast to standard therapy in acute moderate to severe asthma. Double-blind randomised controlled trial. Setting Emergency room/outpatient paediatric services of a tertiary care hospital. Children aged 5-15 years (without prior use of montelukast) with acute moderate to severe asthma exacerbation, as defined using Modified Pulmonary Index Score (MPIS) > or =9, were

EvidenceUpdates2010

10. Can montelukast shorten prednisolone therapy in children with mild to moderate acute asthma? A randomized controlled trial

Can montelukast shorten prednisolone therapy in children with mild to moderate acute asthma? A randomized controlled trial 19656525 2009 11 16 2010 01 07 2013 11 21 1097-6833 155 6 2009 Dec The Journal of pediatrics J. Pediatr. Can montelukast shorten prednisolone therapy in children with mild to moderate acute asthma? A randomized controlled trial. 795-800 10.1016/j.jpeds.2009.06.008 To examine whether outpatient post-stabilization therapy with montelukast produces more treatment failures than (...) prednisolone. In this randomized, double-blind, double-dummy non-inferiority trial, 130 children 2 to 17 years of age with mild to moderate acute asthma stabilized with prednisolone in the emergency department received 5 daily treatments with either prednisolone or montelukast after discharge. The primary outcome was treatment failure within 8 days (ie, an asthma-related unscheduled visit, hospitalization, or additional systemic corticosteroids). The rates of treatment failure were 7.9% in the prednisolone

EvidenceUpdates2010

11. The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis

The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis The role of inhaled corticosteroids and montelukast in children with mild-moderate asthma: results of a systematic review with meta-analysis Castro-Rodriguez JA, Rodrigo GJ CRD summary This review concluded (...) that inhaled corticosteroids led to less asthma exacerbations compared with montelukast for the prevention of asthma exacerbations in children with mild-to-moderate persistent asthma. Although there was uncertainty related to some aspects of the reporting of the review, the authors’ conclusions reflected the evidence presented and appear to be broadly reliable. Authors' objectives To assess the efficacy of inhaled corticosteroids and montelukast for the prevention of asthma exacerbations in children

DARE.2010

12. Economic evaluation of quality-of-life improvement with second-generation antihistamines and montelukast in patients with allergic rhinitis

Economic evaluation of quality-of-life improvement with second-generation antihistamines and montelukast in patients with allergic rhinitis Economic evaluation of quality-of-life improvement with second-generation antihistamines and montelukast in patients with allergic rhinitis Economic evaluation of quality-of-life improvement with second-generation antihistamines and montelukast in patients with allergic rhinitis Saverno KR, Seal B, Goodman MJ, Meyer K Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of several second-generation antihistamines (levocetirizine, desloratadine, and fexofenadine) and montelukast for uncomplicated allergic rhinitis, focusing on improvements in quality

NHS Economic Evaluation Database.2009

13. Montelukast versus inhaled corticosteroids as monotherapy for prevention of asthma: which one is best?

Montelukast versus inhaled corticosteroids as monotherapy for prevention of asthma: which one is best? Montelukast versus inhaled corticosteroids as monotherapy for prevention of asthma: which one is best? Montelukast versus inhaled corticosteroids as monotherapy for prevention of asthma: which one is best? Miceli Sopo S, Onesimo R, Radzik D, Scala G, Cardinale F CRD summary The review’s conclusion appeared to be that inhaled corticosteroids were effective and should be the first choice (...) treatment for paediatric persistent asthma, with montelukast as a possible alternative in children unable to use inhaled corticosteroids. The reliability of these conclusions is unclear given numerous limitations in the conduct and reporting of the review. Authors' objectives To compare the effectiveness of montelukast compared with inhaled corticosteroids as monotherapy in the prevention of asthma in children. Searching MEDLINE was searched (up to December 2008) for English-language papers. Search

DARE.2009

14. Once daily oral controller therapy with low dose theophylline or montelukast was not effective in poorly controlled asthma

Once daily oral controller therapy with low dose theophylline or montelukast was not effective in poorly controlled asthma Once daily oral controller therapy with low dose theophylline or montelukast was not effective in poorly controlled asthma | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Once daily oral controller therapy with low dose theophylline or montelukast was not effective in poorly controlled asthma Article Text Therapeutics Once daily oral controller therapy with low dose theophylline or montelukast was not effective in poorly

Evidence-Based Medicine (Requires free registration)2008

15. Pretreatment with Albuterol versus Montelukast for Exercise-Induced Bronchospasm in Children

Pretreatment with Albuterol versus Montelukast for Exercise-Induced Bronchospasm in Children 18294107 2008 02 25 2008 06 03 2013 11 21 0277-0008 28 3 2008 Mar Pharmacotherapy Pharmacotherapy Pretreatment with albuterol versus montelukast for exercise-induced bronchospasm in children. 287-94 10.1592/phco.28.3.287 To compare pretreatment with albuterol versus montelukast added to the current asthma regimen for protection against exercise-induced bronchospasm in children with mild-to-moderate (...) asthma, and to determine whether cysteinyl leukotriene (Cys-LT) concentrations measured in the exhaled breath condensate correlated with response to montelukast. Prospective, randomized, double-blind, double-dummy, crossover study. Asthma clinic at a university-affiliated medical center. Eleven children aged 7-17 years with physician-diagnosed mild-to-moderate asthma for at least 6 months and with self-reported exercise-induced bronchospasm (defined as > or = 15% decrease in forced

EvidenceUpdates2008

16. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review

Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review Joos S, Miksch A, Szecsenyi J, Wieseler B, Grouven U, Kaiser T, Schneider A CRD summary The authors concluded that adding montelukast (...) to inhaled corticosteroids (ICS) improved control of mild to moderate asthma, and that salmeterol was at least as effective as montelukast as an add-on therapy, but that montelukast may be safer long term. These conclusions may require some caution in interpretation due to the scarcity of good quality data and heterogeneity between the studies. Authors' objectives To evaluate the medium to long-term use of montelukast as add-on therapy to inhaled corticosteroids (ICS) in adolescents and adults

DARE.2008